← All trials
NCT04691154
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2021
- Primary completion
- Oct 31, 2022
- Completion date
- Aug 31, 2023
- First posted
- Dec 31, 2020
- Last posted
- Nov 18, 2021
- Enrollment
- 60
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Pharmosa Biopharm Inc.Lead sponsor
- Harvard UniversityOverall official - principal investigator
- PPDCollaborator
- Arizona Pulmonary SpecialistsOverall official - principal investigator
- University of PittsburghOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.